C-0ZIFSentcell
sMAC, T cell rejuvenation, NCEs
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-0ZIF
C-0ZIFC-0ZIFsMAC, T cell rejuvenation, NCEs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Sentcell sMAC, T cell rejuvenation, NCEs
Sentcell describes itself as an exclusive NCE company developing first-in-class human rejuvenating therapies by rational design focused on the sMAC pathway. Its work centers on T cells, immune senescence, telomere transfer, and compounds intended to reverse or delay ageing-related cellular fate. The company states that it develops pharmaceutical classes derived from anti-ageing principles across biological phenomena.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Sentcell — Early mechanism · Lower middle. Derived deterministically from 9 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical).…
Source: Deterministic